One of the Major Drivers of the Antibody Contract Manufacturing Market Is the Surge In Clinical Trials Fuels The Antibody Contract Manufacturing Market Growth
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Antibody Contract Manufacturing Market Across 2026–2030?
The antibody contract manufacturing market has experienced significant growth in recent years. It is anticipated to expand from $16.79 billion in 2025 to $19.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.0%. This historical growth can be attributed to factors such as the increasing number of biologics development pipelines, heightened outsourcing by biopharmaceutical companies, the expansion of mammalian cell culture platforms, growing clinical trial activity for antibodies, and the availability of specialized cmo infrastructure.
The antibody contract manufacturing market is projected to experience swift expansion in the coming years. This market is anticipated to reach a valuation of $34.72 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.8%. This expansion during the forecast period can be attributed to several factors, including the increasing need for commercial-scale antibody production, heightened investments in advanced biologics, a greater emphasis on manufacturing models that are cost-effective, the widening scope of personalized medicine pipelines, and a rise in regulatory green lights for antibody-based treatments. Key trends anticipated during this period encompass an increase in large-scale antibody manufacturing capabilities, the growing acceptance of single-use bioprocessing systems, an escalating demand for bispecific antibodies and ADCs, a stronger focus on adaptable and scalable manufacturing approaches, and an elevated commitment to regulatory adherence and quality management.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12665&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Antibody Contract Manufacturing Market?
The increasing volume of clinical trials is anticipated to fuel the expansion of the antibody contract manufacturing market in the future. These trials are research studies involving human subjects, designed to assess the safety and efficacy of novel medical treatments, interventions, or diagnostic methods. As the count of clinical trials utilizing antibody-based therapeutics or diagnostics grows, there is an escalating demand for high-quality antibodies, necessitating a prompt and compliant supply for these trials. A notable example is data from May 2023, where ClinicalTrials.gov, an entity of the National Institutes of Health (NIH), a US-based government agency tasked with medical research, reported a rise in registered clinical trial studies across all 50 states of the United States and 221 countries. The number increased from 399,499 in 2022 to 437,533 in 2023. Furthermore, approximately 241,498 studies, constituting 53% of the overall total, were registered beyond the United States, in contrast to 140,492 studies (31%) that were registered solely within the United States. Consequently, the increasing volume of clinical trials is a key factor propelling the expansion of the antibody contract manufacturing market.
What Segmentation Levels Are Considered In The Antibody Contract Manufacturing Market?
The antibody contract manufacturing market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Polyclonal Antibodies, Other Products
2) By Source: Mammalian, Microbial
3) By Scale Of Operation: Preclinical, Clinical, Commercial
4) By End-User: Biopharmaceutical Companies, Research Laboratories, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Therapeutic Monoclonal Antibodies, Diagnostic Monoclonal Antibodies
2) By Polyclonal Antibodies: Research Polyclonal Antibodies, Therapeutic Polyclonal Antibodies
3) By Other Products: Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Fusion Proteins
What Trends Are Projected To Affect The Antibody Contract Manufacturing Market?
Companies prominent in the antibody contract manufacturing market are prioritizing the development of innovations, like single-use technology, which serves to lessen cross-contamination dangers and cut down operational expenditures. Single-use technology (SUT) refers to components and systems that are disposable, employed in biopharmaceutical production processes. For example, in September 2024, Merck & Co., a US-based pharmaceutical company, introduced the Mobius ADC Reactor, engineered to improve the manufacturing of antibody-drug conjugates. This novel single-use reactor, specifically created for antibody drug conjugate manufacturing, significantly elevates production efficiency by 70% when compared to conventional stainless steel or glass techniques. Its disposable architecture lowers cross-contamination risks and operational costs, enabling faster project turnovers. Moreover, advanced film technology boosts bag durability and leak resistance, safeguarding the integrity of highly potent active pharmaceutical ingredients. This innovation assists biopharmaceutical firms in producing vital therapies more securely and effectively.
Which Leading Firms Are Contributing To The Growth Of The Antibody Contract Manufacturing Market?
Major companies operating in the antibody contract manufacturing market are Lonza Group AG, Catalent Inc, Samsung Biologics Co Ltd, Wuxi Biologics Cayman Inc, Thermo Fisher Scientific Inc, Boehringer Ingelheim BioXcellence, AGC Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie Inc, Charles River Laboratories International Inc, mAbxience, KBI Biopharma Inc, Abzena Ltd, Just-Evotec Biologics, Northway Biotech, Cerbios-Pharma, Scorpius BioManufacturing, Lotte Biologics, Rentschler Biopharma SE, Cytiva (Life Sciences CDMO), Xcellon Biologics, Celonic AG, Syngene International Ltd
Read the full antibody contract manufacturing market report here:
Which Regions Are Projected To Dominate The Antibody Contract Manufacturing Market In The Coming Years?
North America was the largest region in the antibody contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Antibody Contract Manufacturing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12665&type=smp
Browse Through More Reports Similar to the Global Antibody Contract Manufacturing Market 2026, By The Business Research Company
Biosimilar Monoclonal Antibodie Global Market Report
Research Antibodie And Reagent Global Market Report
Conjugated Monoclonal Antibodie Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
